BioNTech Investor Day Presentation Deck

mRNA technology Each mRNA format is optimized for specific applications Targeted application Multiple mRNA formats Backbone-optimized uridine mRNA (URNA) Cap UTR Antigen Cap UTR Backbone-optimized nucleoside-modified mRNA (modRNA) ש UTR ψ ψψ UTR Antigen A30-L-A70 A30-L-A70 Self-amplifying mRNA (saRNA) Cap VUTR Replicase SGP Antigen VUTR A30-L-A70 Cap UTR Replicase Cap VUTR Antigen Cap VUTR Antigen Cap VUTR Antigen Trans-amplifying mRNA (taRNA) UTR A30-L-A70 VUTR A30-L-A70 VUTR A30-L-A70 VUTR A30-L-A70 Potent T cell response Repeat administration Potent B cell response Non-immunogenic vector Sustained expression High potency at low dose Sustained expression High potency at low dose Ability to co-develop multiple antigens B cell וש WAN APC TCR וש MHC Antibodies Y T cell Cytokines. Antigens 1 Antigens 2 Antigens 3 حال 80% og so 0808 Platforms Infectious disease vaccines mRNA-encoded antibodies mRNA-encoded cytokines D 111 D Shared antigen mRNA vaccines Individualized neoantigen mRNA vaccines Infectious disease vaccines Multi-platform engine BIONTECH 30

View entire presentation